Devices, vectors and methods for inducible ischemia cardioprotection

• US 20080081354A1
• Filed: 10/02/2006
• Published: 04/03/2008
• Est. Priority Date: 10/02/2006
• Status: Abandoned Application

• Current Assignee: Cardiac Pacemakers Incorporated (Boston Scientific Corporation)
• Original Assignee: Cardiac Pacemakers Incorporated (Boston Scientific Corporation)
• Inventors: Ruble, Stephen, Qu, Jihong, Kramer, Andrew P.
• Application Number:
  US11/541,757
• Publication Number:
  US 20080081354A1
• Time in Patent Office: Days
• US Class Current: 435/69.1
• CPC Class Codes: A61K 48/0058 Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct
• CPC Class Codes: A61P 9/10 for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
• CPC Class Codes: C12N 15/85 for animal cells
• CPC Class Codes: C12N 2800/40 Systems of functionally co-operating vectors
• CPC Class Codes: C12N 2830/002 inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor
• CPC Class Codes: C12N 2830/008 cell type or tissue specific enhancer/promoter combination

Abstract

Vectors, systems having implantable devices and methods useful to detect or treat ischemia are provided.

Claims

1. A vector system, comprising:

a) a first vector comprising a transcriptional regulatory region which includes an organ-specific, tissue-specific or cell-specific, or energy-regulated, transcriptional regulatory element operably linked to a first open reading frame for a gene product that is unstable under normoxic conditions, stable under hypoxic conditions and binds a specific DNA sequence; and

b) a second vector comprising a transcriptional regulatory region comprising the specific DNA sequence operably linked to a second open reading frame for a therapeutic gene product, cardioprotective gene product or biomarker.

2. The vector system of claim 1 wherein the transcriptional regulatory region in the first vector comprises a cardiac-specific transcriptional regulatory element.

3. The vector system of claim 1 wherein the first open reading frame encodes a hypoxia induced gene product.

4. The vector system of claim 1 wherein the second open reading frame encodes a receptor.

5. The vector system of claim 4 wherein the second open reading frame encodes an acetylcholine receptor (AChR).

6. The vector system of claim 1 wherein the second open reading frame encodes an endothelial nitric oxide synthase (eNOS).

7. The vector system of claim 1 wherein the second open reading frame encodes a hemeoxygenase (HO).

8. The vector system of claim 1 wherein the second open reading frame encodes a heat shock protein (HSP).

9. The vector system of claim 1 wherein the second open reading frame encodes Akt.

10. The vector system of claim 1 wherein the second open reading frame encodes a secreted protein.

11. The vector system of claim 10 wherein the second open reading frame encodes secreted alkaline phosphatase (SEAP).

12. The vector system of claim 1 wherein the second open reading frame encodes a nonvertebrate cell associated biomarker.

13. The vector system of claim 1 wherein the second open reading frame encodes a growth factor.

14. The vector system of claim 13 wherein the second open reading frame encodes vascular endothelial growth factor (VEGF).

15. The vector system of claim 1 wherein the second open reading frame encodes a cytokine.

16. The vector system of claim 1 wherein the second open reading frame encodes an anchor protein.

17. The vector system of claim 16 wherein the second open reading frame encodes a sodium iodide symporter (NIS).

18. The vector system of claim 1 wherein the expression of the second open reading frame in an effective amount in cells of a mammal prevents, inhibits or treats cardiac ischemia in the mammal.

19. A mammalian cell having the vector system of claim 1.

20. The mammalian cell of claim 19 which is a stem cell.

34. A method to detect ischemia, comprising:

a) providing a mammal having cells comprising the vector system of claim 1, wherein the second open reading frame encodes a secretable biomarker or a gene product which binds sodium, phosphorus, iodine, carbon, or gadolinium, or an analog thereof; and

b) detecting the secretable biomarker or the protein which binds sodium, phosphorus, iodine, carbon, or gadolinium, or an analog thereof in the mammal.

35. The method of claim 34 further comprising delivering to the mammal electrical therapy in response to detection of the secretable biomarker.

36. The method of claim 34 wherein the secretable biomarker comprises SEAP.

37. The method of claim 34 wherein an implantable device detects the secreted biomarker.

38. The method of claim 34 wherein the location or presence of the protein which binds sodium, phosphorus, iodine, carbon, or gadolinium, or an analog thereof is detected by administering radioactive sodium, phosphorus, iodine, carbon, or gadolinium, or an analog thereof, or a molecule containing radioactive sodium, phosphorus, iodine, carbon, or gadolinium, or an analog thereof, or gadolinium.

39. A method to treat ischemia, comprising introducing the vector system of claim 1 to a mammal, wherein the second open reading frame encodes a therapeutic or cardioprotective gene product.

21. A system, comprising;

a composition comprising at least two vectors, wherein a first vector comprises a transcriptional regulatory region which includes an organ-, tissue- or cell-specific, or energy-regulated, transcriptional regulatory element operably linked to a first open reading frame for a gene product that is unstable under normoxic conditions, stable under hypoxic conditions and binds a specific DNA sequence, and wherein a second vector comprises a transcriptional regulatory region comprising the specific DNA sequence linked to a second opening reading frame for a therapeutic gene product or a cardioprotective gene product; and

an implantable device adapted to deliver one or more of electrical, biologic, or drug therapy which enhances the efficacy of the therapeutic or cardioprotective gene product.

22. The system of claim 21 wherein the tissue-specific transcriptional regulatory element is cardiac-specific.

23. The system of claim 21 wherein the first open reading frame encodes hypoxia inducible factor.

24. The system of claim 21 wherein the first open reading frame encodes cAMP regulatory element binding protein.

25. The system of claim 21 wherein the implantable device comprises an ischemia detector to detect an ischemia event.

26. The system of claim 25 wherein the implantable device comprises a sensor to sense a secreted alkaline phosphatase (SEAP) level, and the ischemia detector is adapted to detect the ischemia event using the SEAP level.

27. The system of claim 21 wherein the implantable device comprises a neurostimulator.

28. The system of claim 21 wherein the implantable device comprises a cardiac pacemaker.

29. The system of claim 21 wherein the implantable device comprises a gene regulatory signal delivery device.

30. The system of claim 21 wherein the implantable device comprises a drug delivery device.

31. The system of claim 21 wherein the first and second vectors are in donor mammalian cells.

32. The system of claim 31 wherein the first and second vectors are in mammalian cardiac cells.

33. The system of claim 31 wherein the first and second vectors are in mammalian stem cells.